GlassScriptPhysician profile
Christopher Y Yee
NPI 1891012860
$5,552.33
in general payments reported to CMS, 2019-2025
32 companies · $1,786 in 2025
The $1,786 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $653 · 2021: $650 · 2022: $1,367 · 2023: $497 · 2024: $221 · 2025: $1,786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,257 · Food and Beverage: $1,204 · Education: $44.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,257.05 |
| Food and Beverage | $1,203.63 |
| Education | $44.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noah Medical Corporation | $1,296.79 | 2025 | Galaxy |
| Glaxosmithkline, LLC. | $899.31 | 2019-2025 | Nucala, Trelegy Ellipta |
| Intuitive Surgical, INC. | $540.24 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $523.38 | 2021-2023 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $479.22 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.14 | 2019-2024 | Stiolto Respimat, Ofev |
| Insmed, INC. | $259.75 | 2020-2022 | |
| Amgen INC. | $241.04 | 2020-2025 | Tezspire |
| Mylan Specialty L.P. | $95.89 | 2020-2024 | |
| La Jolla Pharmaceutical Company | $86.87 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $86.02 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $70.03 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $53.00 | 2020-2025 | Keytruda |
| Genentech USA, INC. | $50.77 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $45.26 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $42.93 | 2020-2021 | |
| Apria Healthcare LLC | $29.92 | 2021 | |
| Novartis Pharmaceuticals Corporation | $28.42 | 2025 | |
| Electromed, INC. | $25.06 | 2022 | |
| Abbott Laboratories | $24.61 | 2022 | |
| Covidien LP | $23.85 | 2019 | |
| United Therapeutics Corporation | $21.90 | 2024 | Tyvaso |
| Therapeuticsmd, INC. | $21.33 | 2022 | |
| Janssen Biotech, INC. | $21.27 | 2019 | |
| Axsome Therapeutics, INC. | $20.55 | 2023 | Sunosi |
| Pulmonx Corporation | $20.51 | 2020 | |
| Lilly USA, LLC | $19.03 | 2025 | Zepbound |
| Ultragenyx Pharmaceutical INC. | $18.33 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.22 | 2022 | |
| Hologic Sales and Service, LLC | $17.57 | 2022 | |
| Grifols USA, LLC | $17.09 | 2021 | |
| Genzyme Corporation | $15.03 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.